Welcome to our dedicated page for Rafael Holdings SEC filings (Ticker: RFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to track both a biotech pipeline and commercial real-estate income in one report? Rafael Holdings’ SEC disclosures weave R&D milestones, infusion-technology sales and lease agreements into hundreds of pages. Finding where drug-trial costs sit, or when a building lease renews, can drain hours.
Stock Titan’s platform delivers the solution. Our AI parses every Rafael Holdings annual report 10-K simplified, flags segment footnotes in each Rafael Holdings quarterly earnings report 10-Q filing, and sends instant alerts on Rafael Holdings 8-K material events explained. Interactive summaries translate accounting language into plain English, so understanding Rafael Holdings SEC documents with AI feels effortless. Need to monitor management moves? Real-time dashboards stream Rafael Holdings Form 4 insider transactions real-time, letting you spot trends before the market reacts.
Here’s what investors uncover:
- Clinical spend vs. progress for lead oncology assets in the 10-K
- Lease revenue swings broken down by property in the 10-Q
- Board proposals and Rafael Holdings proxy statement executive compensation details
- Every Rafael Holdings insider trading Form 4 transactions alongside AI commentary
Whether you’re comparing quarter-over-quarter R&D burn, studying Rafael Holdings earnings report filing analysis, or vetting Rafael Holdings executive stock transactions Form 4 before a catalyst, our comprehensive, real-time feed keeps you ahead—all in one place and explained simply.
Joshua M. Fine, Chief Operations Officer of Rafael Holdings, Inc. (RFL), filed a Form 3 reporting ownership following an event dated 08/04/2025. He holds 9,380 Class B common shares (held jointly with his wife) and stock options totaling 137,881 shares from five grants exercisable 2021–2025 with exercise prices ranging from $1.00 to $21.16. The shares and options were received or converted in connection with the business combination with Cyclo Therapeutics on March 25, 2025.
Form 3 highlights: Director N. Scott Fine has filed his initial beneficial-ownership report after the 14 Jul 2025 business-combination event between Rafael Holdings (RFL) and Cyclo Therapeutics. He directly owns 335,348 Class B shares, including 3,525 held jointly with his spouse. In addition, he holds derivative rights on 373,945 Class B shares via five option grants (strikes $1.90-$21.16, expiries 2031-2035) and three warrants (strikes $2.70-$184.10, expiries 2025-2027). All securities were exchanged from prior Cyclo awards. The filing signals meaningful insider equity alignment but also identifies potential future dilution should the options and warrants be exercised.
Rafael Holdings, Inc. (RFL) has filed a Form S-8 registration statement to cover 1,393,077 additional shares of Class B common stock for employee equity compensation. The filing registers (i) 774,375 shares related to the amended and restated 2021 Rafael Holdings Equity Incentive Plan and (ii) 618,702 shares issuable under the Cyclo Therapeutics 2021 Omnibus Equity Incentive Plan.
The Cyclo shares stem from the 25 March 2025 merger in which Cyclo Therapeutics became a wholly owned subsidiary; all outstanding Cyclo options were assumed by Rafael and converted into options for Rafael Class B stock on substantially similar terms. The S-8 ensures that awards granted or to be granted under both plans are properly registered, allowing the company to issue shares upon exercise or vesting without further SEC registration.
The filing includes customary incorporation by reference of Rafael’s most recent 10-K, subsequent 10-Qs, numerous 8-Ks detailing merger progress, and exhibits such as legal opinions and auditor consents. Standard Delaware indemnification provisions for directors and officers are reiterated. No new financial results, capital-raising activities, or changes to business strategy are disclosed; the document is strictly administrative and facilitates post-merger equity compensation.
Rafael Holdings (RFL) Form 4 filing – CFO David Polinsky reported a routine tax-withholding transaction on 06/21/2025. The company withheld 2,347 Class B common shares, valued at $1.595 per share, to cover statutory taxes triggered by the vesting of restricted stock units. The filing is coded “F,” confirming the shares were not sold in the open market but surrendered to the issuer. Following the transaction, the CFO continues to beneficially own 268,075 Class B shares, comprising 76,882 shares held outright, 69,943 vested restricted shares, and 121,250 unvested restricted shares that will vest in scheduled tranches through 01/13/2029. No new shares were acquired and no open-market sale was executed; the transaction has no direct cash impact and does not signal a change in insider sentiment. The filing maintains broad insider alignment, as the CFO retains a meaningful equity stake worth roughly $0.43 million at the reported price. Overall, the Form 4 appears administratively routine with negligible impact on the company’s capital structure or market perception.
FAQ
What is the current stock price of Rafael Holdings (RFL)?
What is the market cap of Rafael Holdings (RFL)?
